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Abstract 
 
BACKGROUND 
Combining several anticancer agents can increase the overall anti-tumor action, but 
at the same time, it can also increase the overall observed toxicity. Adaptive dose-
escalation designs for drug combinations have recently emerged as an attractive 
alternative to algorithm-based designs, and they seem more effective in combination 
recommendations. These methods are not used in practice currently. Our aim is to 
describe international scientific practices in the setting of phase I drug combinations 
in oncology. 
MATERIAL AND METHODS 
A bibliometric study on phase I dose-finding combination trials was conducted using 
the MEDLINE® PubMed database between January 1, 2011 and December 31, 
2013. Sorting by abstract, we selected all papers involving a minimum of two-agents 
and then retained only those in which at least two agents were dose-escalated. 
RESULTS 
Among the 847 references retrieved, 162 papers reported drug-combination phase I 
trials in which at least two agents were dose-escalated. In 88% of trials, a traditional 
or modified 3+3 dose escalation design was used. All except one trial used a design 
developed for single-agent evaluation. Our study suggests that drug-combination 
phase I trials in oncology are very safe, as revealed by the calculated median DLT 
rate of 6% at the recommended dose, which is far below the target rate in these trials 
(33%). 
We also examined requirements of phase I clinical trials in oncology with drug 
combinations and the potential advantages of novel approaches in early phases.  
CONCLUSION 
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Efforts to promote novel and innovative approaches among statisticians and 
clinicians appear valuable. Adaptive designs have an important role to play in early 
phase development. 
 
Keywords: Drug combinations, Phase I trials, Dose-finding 
  
5 
 
Introduction 
Phase I trials in oncology are dose-finding studies that seek to determine the dose to 
recommend for further evaluation (recommended phase II dose [RP2D]). These trials 
are designed to obtain reliable information on the safety, pharmacokinetics, and 
mechanism of action of a drug. In oncology, dose-finding studies focus on 
determining the highest dose of a new drug with acceptable toxicity [1-2]. They are 
subject to the ethical constraint of minimizing the number of subjects treated at 
unacceptable toxic dose levels. Toxicity is measured as a binary endpoint, denoted 
as “dose limiting toxicity” (DLT), mainly using National Cancer Institute Common 
Toxicity Criteria. Most dose-escalation methods were developed for cytotoxic agents 
with the assumption that toxicity increases with dose in a monotonic fashion. 
Therefore, the RP2D has traditionally been the highest safe dose, called the 
“maximum tolerated dose” (MTD). These methods were specifically designed for the 
evaluation of single agents. In clinical practice, the traditional “3+3” dose escalation 
design or a modification thereof are the most frequently used dose-escalation 
methods in phase I trials [3].  
Drug combinations have been introduced with the goal of improving treatment 
efficacy by increasing overall anti-tumor activity and, presumably, survival. 
Successful drug combinations include a combination of cytotoxic agents for the 
treatment of germ-cell tumors and lymphoma, polychemotherapy for the treatment of 
germ-cell tumors [4-5], combinations of trastuzumab with a taxane for HER2-positive 
breast cancer [6], and a combination of BRAF and MEK inhibitors [7]. Although it can 
reasonably be assumed that toxicity increases with dose for a single drug, the 
determination of the relationship between toxicity and doses of multiple drugs 
remains elusive. When combining two or more agents, there may be a potential 
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synergistic effect, not only in terms of efficacy, but also in terms of toxicity [8]. 
Therefore,  when combining several agents, the ordering between combinations 
according to their DLT rates is important. However, only partial ordering of DLT rates 
can be anticipated when the dose of only one drug is being escalated, whereas the 
dose of the other drugs in the combination is kept fixed (Figure 1). That is, referring to 
Figure 1a, in a row (or column), one agent is fixed while the other is increased. In this 
case, the DLT rates are increased with the dose of the agent. All these order 
relations in rows and columns (shown with the symbol inferior “<”) lead to “a partial 
ordering of DLT rates” given in Figure 1a. For example, if 2 agents with 3 dose levels 
are considered, when a monotonic and increasing relationship is assumed with 
respect to both agents then a partial toxicity order is known between the 9 
combinations. The lowest combination is dose level 1 of agent 1 combined to dose 
level 1 of agent 2 (1,1) and the highest combination is dose level 3 of agent 3 
combined with dose level 3 of agent 2 (3,3). Presumably, combination (1,2) is less 
toxic than (2,2), which is also presumably less toxic than (3,2), etc. However, on a 
diagonal, when the dose of one agent is increased while the dose of the other is 
decreased, it is not known which combination is more toxic. For instance, is the (1,2) 
combination more or less toxic than the (2,1) combination? Therefore, several toxicity 
orderings between combinations are possible (two examples are given in Figures 1b 
and 1c). 
In practice, drug-combination phase I trials raise several challenging points to 
be defined prior to the trial onset [9-17]: 1) starting dose of each agent; 2)  choice of 
the dose range of each agent and the number of combinations to be evaluated; and 
3) total sample size that is strongly related to the number of possible combinations. In 
this study, we aimed at evaluating how drug-combination phase I trials in oncology 
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have been designed in the last three years and what the principal investigator’s 
choices were with regard to the dose range, number of combinations, and statistical 
design. 
 
Material and methods 
All drug-combination phase I trials published between January 1, 2011 and 
December 31, 2013 were reviewed (Figure 2). We restricted our review to phase I 
combination trials where at least two drugs were planned to undergo dose escalation. 
Trials involving radiation therapy or drugs other than cytotoxic agents and molecularly 
targeted agents (MTAs) were excluded. MTAs were defined in our review as 
anticancer agents that selectively target molecular pathways, as opposed to DNA, 
tubulin or cell division machinery. Hormonal therapy and biological therapeutics, such 
as immunotherapy, were included. 
We performed a MEDLINE® PubMed search using the following terms: 
“Clinical Trial, Phase I[ptyp] AND cancer[MeSH] AND "2011/01/01"[PDAT] : 
"2013/12/31"[PDAT AND (combination OR combine OR combined OR combining)”. 
Among 847 references retrieved, 162 papers reported on a drug combination phase I 
trial meeting our inclusion criteria, 381 papers involved drug combinations where only 
one agent was dose-escalated, while the others were fixed (Figure 2).  
The following data were recorded: the number of drugs undergoing dose 
escalation, the types of drugs (cytotoxic agent versus MTA), the number of dose 
levels planned for each drug, justification of the starting doses, number, choice and 
justification of drug combinations, dose-escalation design used, addition of drug 
combinations during the trial, number of patients included, and target toxicity level. 
We also performed a quality control analysis of the reviewed papers. 
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In this review, the lowest combination is defined as the combination 
corresponding to the lowest dose levels planned of each agent. A monotonic and 
increasing dose-toxicity relationship with respect to both agents signifies that when 
fixing one agent or the other to a certain dose independently, the DLT rate of the 
combination increases with the dose level of the remaining agent. 
 
Results 
Characteristics of the drugs 
The 162 phase I trials involved 340 drugs that underwent dose escalation. In the 
majority of the trials, only 2 drugs underwent dose escalation (Table 1). Trials that 
involved only cytotoxic agents, only MTAs, and a combination of cytotoxic agents and 
MTAs were roughly equally distributed.  
 
Dose levels 
The median number of patients included per trial was 25 [range: 7-136] (Table 1). In 
69% of cases, the starting combination in the trial was the one associated with the 
lowest dose level of each agent considered in the trial. The starting dose used in the 
trial was justified (short explanation or only references) in 35% of the trials, 
respectively (Figure 3). The dose levels of each agent involved in the combinations of 
the clinical trial were justified in only 47 publications (29%). Results of a quality 
control analysis are provided in Figure 3. 
 
Dose combinations 
The median number of planned combinations in the trial protocol was 5 [range: 2-16], 
5.5 [range: 3-15] and 12 [range: 12-12] in trials combining two, three, and four drugs, 
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respectively. The median number of actually evaluated combinations was 4 [range: 2-
12], 4 [range: 2-9] and 3 [range: 3-3] in trials combining two, three, and four drugs, 
respectively. 
The median ratio of the number of planned combinations to the number of 
possible combinations (defined as the number of planned combinations divided by 
product of the number of doses levels of each agent) was 0.67 [range: 0.25-1], 0.24 
[range: 0.17-0.63] and 0.13 [range: 0.13-0.13] in trials combining two, three, and four 
drugs, respectively.  
 
Dose escalation method 
In most trials, a traditional 3+3 or a modified 3+3 dose escalation design was used 
(Table 1). Only one trial used a design developed for combination trials. Most of the 
selected papers assumed a monotonic and increasing dose-toxicity relationship, in 
62% of trials, whereas 38% of papers assumed only a partial monotonic and 
increasing dose-toxicity relationship. 
 In 24% of the trials, additional drug combinations were evaluated during the 
trial for safety reasons.   
 
Safety 
The DLT target rate associated with the recommended dose was 33% in most 
studies (Table 1). However, according to the number of patients and DLTs reported 
at the RP2D, the calculated median DLT rate at the recommended dose was 6% 
[range: 0%-40%]. Nevertheless, in only 4% of trials was the DTL rate estimated by 
the authors at the recommended combination for further studies. 
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In 3% of the studies, the trial was stopped at the first dose level due to DLTs. 
Five trials were stopped for reasons relating to over-toxicity; that is, the lowest 
combination evaluated in the trial was considered too toxic and the trial was abruptly 
halted without finding a tolerable combination. Fifty-six per cent of the trials found the 
MTD according to its initial definition, and 11% of trials found an MTD without 
observing any DLTs throughout the trial. In 48% of trials, the progress observed in 
the trial did not match the initial planned method. The trials that did not match the 
intended plan were all 3+3 or modified 3+3 statistical designs. The main observed 
differences from planning were: (1) difference in the planned number of patients per 
cohort with no justification and (2) a different allocation rule during the trial. 
 
Discussion 
Our study suggests that drug-combination phase I trials in oncology are safe. Overall, 
however, the starting doses of the drugs in the trials reviewed, as well as the dose 
levels and the dose-escalation steps, were barely justified. In addition, the dose 
levels explored in the drug-combination phase I trials included in our study did not 
reflect the entire space of possible drug combinations. In most of cases, dose levels 
seemed to be arbitrarily decided. It remains to be evaluated whether non-explored 
drug combinations would have been able to produce increased anti-tumor activity 
without jeopardizing patient safety.  
Only a limited number of combinations were explored and only a sub-set of 
combinations was evaluated, despite the larger number of possible combinations. In 
our MEDLINE® PubMed search, the median ratio of the number of combinations 
considered to the number of possible combinations indicated that approximately one-
third of the combinations were not considered for two-drug combinations. This 
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indicates that trial investigators may have selected the combinations to be evaluated 
prior to the trial, and that some combinations were excluded without documented 
rationale. Exploring the entire combination space is obviously not feasible in practice. 
Nevertheless, the choice of the combinations to explore should not be limited by 
partial toxicity ordering.  The design should have the possibility to explore any 
combination estimated to be the best. In fact, due to possible interactions between 
drugs, pre-selecting an arbitrary reduced sub-set of combinations induces a risk in 
selecting a combination with a DLT rate far from target toxicity. Even if the targeted 
DLT proportion was most often about 33% in the papers, the median DLT rate 
associated with the RP2D at the end of the trial was much lower. That could be a 
reason why an intermediate combination was added, in some cases, which induced a 
non-monotonic dose-toxicity relationship in some trials.  
During the review of this paper, the question was raised whether the low DLT rate 
could be due to MTAs for which the toxicity profile is different. Indeed, for these non-
cytotoxic agents, very low toxicities are often observed with sometimes cumulative 
low-grade toxicities that may become dose limiting. The cumulative low-grade 
toxicities partially explain deviance from the intended plan. An FDA guideline [18] 
reported: “…cancer vaccine trials have used the “3 + 3 design” and the results show 
that, except in very rare situations, an MTD for a cancer vaccine may not be 
identified. In these trials, the dose-toxicity curve may be so flat that the highest dose 
that can be administered is limited by manufacturing or anatomic issues rather than 
toxicity. Therefore, this “3+3 design” may not be the most suitable approach to 
gathering information from early phase trials of cancer vaccines, and alternative trial 
designs should be considered.” They added that: “When no DLT is expected or 
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achieved, optimization of other outcomes, such as the immune response, can be 
useful to identify doses for subsequent studies”.  
For this reason, standard dose-finding designs dealing only with toxicity, such as the 
“3+3” do not seem appropriate for some biological agents [19]. First, it is true that the 
dose determination based on less than 33% DLT on the first cycle of treatment for 
molecularly targeted agents is problematic. These non-cytotoxic agents have 
different toxicity profiles than cytotoxic agents. One possible reason for the observed 
low DLT rate at the RP2D could be due to the DLT evaluation only on the first cycle 
of treatment. Physicians can observe no DLT on the first cycle but cumulative low-
grade toxicities that become dose limiting with later cycles of treatment. For this 
reason, they decrease the recommended dose level for phase II (in contrast to the 
statistical design), rendering a low DLT rate (evaluated only on the first cycle) for this 
dose. All cumulative toxicity grades on all available cycles should be considered in 
the statistical analysis for dose recommendations. Furthermore, depending on the 
biological agent, several dose-efficacy relationships could be observed: (1) 
monotonic and increasing; (2) monotonic increasing and then reaching a plateau; 
and (3) monotonic increasing and then decreasing with the dose. In the latter two 
cases, only studying toxicity in the dose-finding process is not sufficient, and efficacy 
should also be considered. Therefore, alternative designs should be developed. 
Adapting the way of doing early phase clinical trials for these innovative molecules is 
important, but changing usual practices in oncology is very complex and difficult. If 
regulatory agencies were to give clear instructions, trial sponsors and investigators 
would need to apply them. There are published statistical designs proposing 
alternative methods [20-22], therefore statistics should not be a limited factor.  
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However, in calculating the median DLT rate for trials in which the combination 
involved cytotoxic agents, we observed a DLT rate of 4%. Therefore, we do not 
believe that this is due to the type of agent but rather to the use of the “3+3” 
algorithm, where the dose retained is the dose under 2 DLTs over 3 or 6 patients. 
Indeed, in the trials studied, either the combination level was associated with no (or 
very few) DLTs, or the highest dose level in the trial did not even reach the target 
toxicity. Thus, due to the small number of patients (3 or 6) with the “3+3” design, the 
estimation is unreliable and often close to 0%. It should be noted that combination 
trials of MTAs included more patients at the RP2D than combination trials of cytotoxic 
agents, perhaps due to the uncertainty on overall toxicity discussed above. That 
could explain the small increased difference in DLT rates despite the toxicity profile of 
MTAs, as the estimation with a greater number of patients is more reliable. 
Most of the drug-combination phase I trial designs used the traditional “3+3” 
design or a modified version. Recent dose-escalation designs have been developed 
for drug combinations but never employed in the trials reviewed [23-30]. In all but one 
trial reviewed, the dose-toxicity relationship was considered to be one-dimensional, 
whereas the reality involved several agents inducing a multi-dimensional issue. Most 
of the time, the problem was brought back into a one-dimensional space by pre-
selecting combinations with a known toxicity order to be evaluated.  
The methods for single agents do not always seem appropriate for 
combination phase I trials in which the doses of several drugs vary, as they are not 
designed to take a multi-dimensional space into account. Several alternative designs 
were proposed for either algorithm-based or design-based combinations that give the 
possibility to explore any appropriate combination in the entire combination space 
according to the accumulated data. Ivanova and Wang proposed an “up-and-down 
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algorithm-type” method with isotonic regression [31] that was used recently in Gandhi 
et al. [32]. Conaway et al. developed a design for multiple agents based on partial 
orders [33] that was used in the publications reviewed in Jones et al. [34]. Other 
authors have proposed model-based designs in which the multi-dimensional feature 
of the entire combination space is taken into account. These methods allow 
considering the entire combination space that includes a large number of 
combinations with non-monotonic relationships. It should be noted that these 
methods do not permit exploring combinations that are estimated to be too toxic. In a 
recent comparison, based on simulations, Riviere et al showed that these designs 
were comparable and had high operational characteristics [30]. However, it is true 
that these designs have only been shown to be effective in simulation studies 
(Riviere et al, Stat Med 2014), and they require the involvement of a statistical expert. 
In a recent editorial, Mandrekar [9] pointed out the importance of using 
adequate methods for the evaluation of combinations. Our bibliometric work supports 
this editorial with a large and detailed study on clinical practice in the phase I settings 
for combination trials. 
Our analysis did not include trials published in abstract form. Although this 
induces a selection bias, the present analysis still provides useful data that may help 
improve the design of drug-combination phase I trials. 
In our review, we did not stated that both agents must be administered at their 
single-agent MTD when in combination. As two agents can have a synergistic, 
antagonistic or independent effect on toxicity, the question of achieving doses (for 
each agent) that nearly approximate the recommended phase II dose is up for 
debate. It is a strong assumption that the addition of both agents at their MTD would 
result in the same toxicity as if administered alone. We believe that considering all 
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combinations of dose levels between the two agents as a possible MTD should be 
acceptable, under medical restrictions and prior knowledge of such combinations. 
The recommended combination at the end of the trial should not be limited to the 
combination of both single-agent MTDs, but the dose-finding process should be 
performed similarly to that of a single-agent in order to recommend the combination 
with a toxicity rate closest to or below a pre-defined target. Indeed, in the same way, 
combining two agents can also induce a synergistic, antagonistic, or independent 
effect on overall efficacy. This point should be discussed for each combination of 
drugs, as the mechanism of action of each agent can differ. 
In conclusion, we believe that the design of drug-combination phase I trials in 
oncology can be improved. We recommend that the starting doses of the drugs, as 
well as the dose levels and the dose-escalation steps, need to be appropriately 
justified. These parameters should be determined with the aim to: 1) ensure patient 
safety; 2) treat as few patients as possible at presumably infra-therapeutic doses; 
and 3) identify the optimal drug combination for further evaluation. We strongly 
support the use of innovative designs that are able, at least in theory, to fulfil these 
requirements.  
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Figure legends 
 
Figure 1. 
(a) Partial known ordering between combinations. (b) Possible orderings 
between combinations according to increasing DLT rates. 
Figure 2.  
Flow chart of the publications found from the MEDLINE® PubMed search. 
Figure 3. 
Control quality of 162 trials reviewed. 
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